SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is experiencing a massive surge in volume, fueled by intense speculation regarding its extremely low public float after a filing revealed a single entity owning 91% of shares. This has ignited strong short squeeze momentum, with the community actively debating comparisons to other volatile runners and anticipating significant upward moves. Amidst this bullish sentiment, some investors are cautioning about potential dilution or delisting risks, creating a highly speculative trading environment.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to widespread community discussion focused on its ultra-low share float and significant short interest, sparking intense speculation about a potential short squeeze. Traders are actively drawing comparisons to past high-volatility stocks, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement. The community is closely monitoring for a breakout above key price levels.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing intense debate as it trades at multi-year lows despite broader market gains, with community sentiment sharply divided. While many express extreme frustration and criticize management for perceived underperformance, a contrarian view highlights strong fundamentals and potential for a significant rebound driven by anticipated midterm election spending and AI integration. The stock's future is a key talking point, especially as it navigates competitive pressures from major tech platforms and awaits upcoming earnings.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending with significant upward momentum, propelled by a recent analyst upgrade to an $80 price target and a favorable environment for AI infrastructure development, including tariff relief and its strategic power capacity. The community is actively debating the sustainability of this rally, with many anticipating major AI deals while others express caution regarding its current valuation amidst a short squeeze.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to a notable price decline, with community discussion frequently pointing to market manipulation and options-related 'max pain' as key drivers. This comes despite multiple analyst upgrades highlighting its AI-powered growth in mobile advertising and e-commerce, leaving investors questioning the immediate market dynamics amidst underlying bullish sentiment for the company's fundamentals.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a key topic following its investor event, where the company significantly raised future revenue guidance and reported a substantially increased backlog, bolstered by a strong cash position. The community is actively debating its high valuation and the presentation quality, even as many anticipate continued long-term growth and potential for a short squeeze in its critical infrastructure and defense autonomous systems sectors. Discussion centers on whether the updated outlook justifies the current price and foreshadows further analyst upgrades.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending due to its pivotal multi-year data center leasing agreement with AMD, which includes a significant initial IT load capacity and options for substantial expansion at its Rockdale site. This deal is driving community excitement, seen as a strategic shift transforming Riot into a leading AI/HPC infrastructure provider with massive power capacity, potentially decoupling its valuation from Bitcoin and drawing comparisons to other major players.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending due to overwhelming positive clinical data, showing sustained complete responses in lymphoma patients, sparking significant community excitement about its potential in cancer treatment. This promising news, coupled with recent global approvals for Anktiva, is fueling a perceived short squeeze and massive trading volume as investors anticipate a major breakthrough in the biotech sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to significant institutional interest, including increased holdings and analyst upgrades, alongside expansion into new iGaming markets like Maine. However, community discussions are highly polarized, grappling with volatility, competitive pressures from prediction markets, and concerns over sports betting integrity following recent scandals. Investors are closely watching these dynamics ahead of upcoming earnings and major sporting events.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing a significant surge following its selection for the U.S. Missile Defense Agency's SHIELD program, part of the broader Golden Dome defense strategy. This news is energizing a strong bullish community, who see it as validation of the company's dual-use satellite technology and a catalyst for a potential short squeeze, despite ongoing discussions regarding its valuation and revenue generation. Many long-term holders are celebrating what they view as a critical step in establishing ASTS as a national strategic asset in the rapidly evolving space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deutsche Bank Aktiengesellschaft Boosts GSK (LON:GSK) Price Target to GBX 1,675

Deutsche Bank Aktiengesellschaft raised their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a research note on Thursday...

GSK (LON:GSK) Shares Pass Above 200-Day Moving Average - Here's Why

GSK (LON:GSK) Share Price Passes Above 200-Day Moving Average - Should You Sell...

GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Here's Why

GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Time to Sell...

Here's Why GSK (GSK) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSKs B7-H3 Antibody Drug Conjugate (ADC)

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (GSK, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1...

Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.read more...

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.read more...

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.</p><h2 class="st-heading-2"><strong>Drug Pricing And Tariff Exemptions</strong></h2><p>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.</p><p>The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.</p><p>“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;</p><h2 class="st-heading-2"><strong>US Manufacturing Commitments</strong></h2><p>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;</p><p>As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;</p><p>Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.</p><h2 class="st-heading-2"><strong>White House Drug Deals Expand</strong></h2><p>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.</p><p>The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Equity

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Current Price	$48.45
Prev Close	$49.12
Open	$48.90
Dividend Yield	4.53%
50-Day Moving Average	$48.44
Beta	0.26
Avg. Volume	3.12M
PE Ratio	13.82

52-Week High	$51.46
52-Week Low	$32.38
Market Capitalization	$99.08B
EPS (Annual)	$1.61
Price to Book	4.55
Revenue Per Employee	$584,193.84
Enterprise Value/EBITDA	N/A

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSKGlaxosmithkline plc - ADR